{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T05:01:00Z","timestamp":1780203660357,"version":"3.54.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005302","name":"University of Illinois Urbana-Champaign","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA173292"],"award-info":[{"award-number":["R01 CA173292"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA216919"],"award-info":[{"award-number":["R01 CA216919"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgery"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.surg.2025.109702","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T20:12:15Z","timestamp":1761250335000},"page":"109702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel therapeutic approach to adrenocortical carcinoma repurposing fingolimod to target sphingolipid metabolism in metastatic disease"],"prefix":"10.1016","volume":"189","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1871-2834","authenticated-orcid":false,"given":"Chitra","family":"Subramanian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli","family":"McNamara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth Wyatt","family":"Croslow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqi","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Kiseljak-Vassiliades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Wierman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan V.","family":"Sweedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.surg.2025.109702_bib1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1210\/jc.2014-2650","article-title":"Brain metastasis in patients with adrenocortical carcinoma: a clinical series","volume":"100","author":"Burotto","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2025.109702_bib2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1210\/clinem\/dgae571","article-title":"The effect of adrenalectomy on overall survival in metastatic adrenocortical carcinoma","volume":"110","author":"Assad","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2025.109702_bib3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/jso.23015","article-title":"Operative management for recurrent and metastatic adrenocortical carcinoma","volume":"105","author":"Datrice","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.surg.2025.109702_bib4","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1210\/jc.2018-00918","article-title":"Predictors of survival in adrenocortical carcinoma: an analysis from the National cancer database","volume":"103","author":"Tella","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2025.109702_bib5","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.surg.2025.109702_bib6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.3390\/cancers12040941","article-title":"Efficacy of the EDP-M scheme plus adjunctive surgery in the management of patients with advanced adrenocortical carcinoma: the brescia experience","volume":"12","author":"Lagana","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.surg.2025.109702_bib7","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.surg.2025.109702_bib8","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bjc.2013.46","article-title":"Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma","volume":"108","author":"Naing","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.surg.2025.109702_bib9","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","article-title":"Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study","volume":"16","author":"Fassnacht","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.surg.2025.109702_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1530\/EJE-09-0804","article-title":"Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma","volume":"162","author":"Wortmann","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.surg.2025.109702_bib11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.surg.2025.109702_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.surg.2025.109702_bib13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2020.07.013","article-title":"Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention","volume":"159","author":"Butler","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.surg.2025.109702_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.577420","article-title":"Alterations of lipid metabolism in cancer: implications in prognosis and treatment","volume":"10","author":"Fernandez","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.surg.2025.109702_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.surg.2021.04.049","article-title":"Identification of novel lipid metabolic biomarkers associated with poor adrenocortical carcinoma prognosis using integrated bioinformatics","volume":"171","author":"Subramanian","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2025.109702_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/tra.12239","article-title":"Sphingolipid metabolism and interorganellar transport: localization of sphingolipid enzymes and lipid transfer proteins","volume":"16","author":"Yamaji","year":"2015","journal-title":"Traffic"},{"key":"10.1016\/j.surg.2025.109702_bib17","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41580-018-0046-6","article-title":"Author correction: sphingolipids and their metabolism in physiology and disease","volume":"19","author":"Hannun","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.surg.2025.109702_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.yexcr.2015.02.025","article-title":"Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy","volume":"333","author":"Newton","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.surg.2025.109702_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.surg.2025.109702_bib20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nprot.2017.013","article-title":"Metabolomics and lipidomics using traveling-wave ion mobility mass spectrometry","volume":"12","author":"Paglia","year":"2017","journal-title":"Nat Protoc"},{"key":"10.1016\/j.surg.2025.109702_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nmeth.3393","article-title":"MS-DIAL: data-independent MS\/MS deconvolution for comprehensive metabolome analysis","volume":"12","author":"Tsugawa","year":"2015","journal-title":"Nat Methods"},{"key":"10.1016\/j.surg.2025.109702_bib22","doi-asserted-by":"crossref","first-page":"9903","DOI":"10.1038\/s41467-024-54137-w","article-title":"MS-DIAL 5 multimodal mass spectrometry data mining unveils lipidome complexities","volume":"15","author":"Takeda","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.surg.2025.109702_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.07.075","article-title":"Novel repurposing of sulfasalazine for the treatment of adrenocortical carcinomas, probably through the SLC7A11\/xCT-hsa-miR-92a-3p-OIP5-AS1 network pathway","volume":"177","author":"Subramanian","year":"2025","journal-title":"Surgery"},{"key":"10.1016\/j.surg.2025.109702_bib24","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s13361-017-1704-1","article-title":"microMS: a python platform for image-guided mass spectrometry profiling","volume":"28","author":"Comi","year":"2017","journal-title":"J Am Soc Mass Spectrom"},{"key":"10.1016\/j.surg.2025.109702_bib25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.jproteome.2c00714","article-title":"Data-driven and machine learning-based framework for image-guided single-cell mass spectrometry","volume":"22","author":"Xie","year":"2023","journal-title":"J Proteome Res"},{"key":"10.1016\/j.surg.2025.109702_bib26","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"key":"10.1016\/j.surg.2025.109702_bib27","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.biomaterials.2011.01.057","article-title":"An overview of tissue and whole organ decellularization processes","volume":"32","author":"Crapo","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.surg.2025.109702_bib28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/oncolo\/oyae029","article-title":"Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches","volume":"29","author":"Chukkalore","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.surg.2025.109702_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/ejendo\/lvac007","article-title":"Elevated sphingosine-1-phosphate lyase leads to increased metabolism and reduced survival in adrenocortical carcinoma","volume":"188","author":"Williams","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.surg.2025.109702_bib30","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.18632\/oncotarget.6564","article-title":"Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.surg.2025.109702_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41467-019-14218-7","article-title":"Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1","volume":"11","author":"Imbert","year":"2020","journal-title":"Nat Commun"}],"container-title":["Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606025005549?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039606025005549?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T04:27:29Z","timestamp":1780201649000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039606025005549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"alternative-id":["S0039606025005549"],"URL":"https:\/\/doi.org\/10.1016\/j.surg.2025.109702","relation":{},"ISSN":["0039-6060"],"issn-type":[{"value":"0039-6060","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel therapeutic approach to adrenocortical carcinoma repurposing fingolimod to target sphingolipid metabolism in metastatic disease","name":"articletitle","label":"Article Title"},{"value":"Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.surg.2025.109702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109702"}}